# A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors

> **NCT06427057** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Urinary System Tumor

## Interventions

- **DRUG:** Cadonilimab plus chemotherapy
- **DRUG:** Cadonilimab plus TKI

## Key facts

- **NCT ID:** NCT06427057
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06427057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06427057, "A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06427057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*